

Cambia[®] (diclofenac potassium) – First-time authorized brand alternative

- On January 3, 2023, Leading Pharma launched an authorized brand alternative of Assertio Therapeutics' [Cambia \(diclofenac potassium\)](#) oral solution.
 - [Par](#), [Annora](#) and [Alkem](#) received FDA approval of AB-rated generic versions of Cambia on May 2, 2016, March 4, 2022, and July 20, 2022, respectively. Launch plans for these generics are pending.
- Cambia is approved for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older).
- Cambia carries a boxed warning for risk of serious cardiovascular and gastrointestinal events.